Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Current Medical Research and Opinion
Douglas E FariesBruce J Kinon

Abstract

Switching medications is common in the treatment of schizophrenia. This study examines the effectiveness of olanzapine therapy following a clinically warranted switch from risperidone during treatment of patients with schizophrenia. This post-hoc analysis used data from the risperidone arm of a randomized, open-label, 1-year study of patients with schizophrenia. Study protocol permitted antipsychotic switching when clinically warranted, and outcomes were assessed with standard psychiatric measures. Statistical analyses assessed changes from pre- to post-medication switch and endpoint comparisons between patients switched from risperidone to olanzapine and patients continued on risperidone. Most patients who switched from risperidone switched to olanzapine (43/60; 71.7%). Average duration of risperidone treatment prior to switching was 86 days (mean modal dose 4.0 mg/day). Most switchers (86%) completed the 1-year study on olanzapine (average duration 241 days; mean modal dose 12.0 mg/day). Following switch to olanzapine, patients experienced significant improvements on clinical (Brief Psychiatric Rating Scale) and social (Quality of Life Inventory) parameters, with similar proportions of patients achieving remission status at e...Continue Reading

References

Mar 1, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Peter P Roy-ByrneAlexander Bystritsky
May 21, 2003·The Journal of Clinical Psychiatry·Peter J WeidenRichard L O'Sullivan
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 6, 2005·Journal of Psychopharmacology·Peter J Weiden
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·S L TunisR A Browne
Apr 22, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sandra L TunisRalph Aquila
Jun 9, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hitoshi TakahashiHisashi Higuchi
Dec 8, 2006·The American Journal of Psychiatry·Susan M EssockJeffrey A Lieberman
Jul 20, 2007·Schizophrenia Bulletin·R A RosenheckMichael Sernyak
Aug 19, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sung-Wan KimJin-Sang Yoon

❮ Previous
Next ❯

Citations

Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Dec 12, 2012·Harvard Review of Psychiatry·Bandar AlAqeel, Howard C Margolese
Dec 15, 2010·The Cochrane Database of Systematic Reviews·Anitha MukundanGary Remington

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here